2025

Duong T, Haselkorn T, Miller B, Coats J, Jensen I, Ward E, Wood M, Graham RJ, Servais L. 2025. A real-world analysis of the impact of X-linked myotubular myopathy on caregivers in the United States. Orphanet J Rare Dis 20(1):224. doi: 10.1186/s13023-025-03583-w.

View Abstract

Desai NR, Piccini JP, Sacks NC, Reichert H, Hooda N, Jiang X, Blood AJ, Holz A, et al. Emergency department visits and inpatient admissions for atrial fibrillation in the United States (US): 2015-2019. Abstract I10, Academy of Managed Care Pharmacy (AMCP) Annual Meeting, Houston, TX. J Manag Care Spec Pharm 31(3-a Suppl):S74; doi: 10.18553/jmcp.2025.31.3-a.s1, March 31-April 3, 2025.

View Abstract

Tao C, Nicholson G, Desai N, Sacks N, Sherwood R, Pokorney S. Budget impact of etripamil for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States. Abstract I9, AMCP Annual Meeting, Houston, TX. J Manag Care Spec Pharm 31(3-a Suppl):S73; doi: 10.18553/jmcp.2025.31.3-a.s1, March 21-April 3, 2025.

View Abstract

Nordyke RJ, Motyka J, Patterson JA. 2025. The association of 340B program drug margins with covered entity characteristics. Inquiry 62(Jan-Dec):469580251324051; doi: 10.1177/00469580251234051. PMID: 4012322.

View Abstract

Wikoff DS, Vincent MJ, Heintz MM, Pastula ST, Reichert H, Klaren WD, Haws LC. 2025. Application of a quantitative uncertainty assessment to develop ranges of plausible toxicity values when using observational data in risk assessment: A case study examining associations between PFOA and PFOS exposures and vaccine response. Toxicol Sci 204(1):96-115; doi: 10.1093/toxsci/kfae152. PMID: 39792025.

View Abstract

Pastula ST, Bylsma LC, Rege SV, Lewis RJ, Movva N. 2025. Scoping review of indices to measure a community’s health status. Popul Health Manag 28(1):37-49; doi: 10.1089/pop.2024.0138. PMID: 39558762.

View Abstract

Shafrin J, Wang S, Sharma K, Spurrier K, Nordyke RJ. 2025. Will the Institute for Clinical and Economic Review’s shared savings approach decrease value-based prices most for the most severe diseases? Value Health 28(1):25-30; doi: 10.1016/j.val.2024.09.002. PMID: 39357669.

View Abstract

Patterson JA, Motyka J, Salih R, Nordyke RJ, O’Brien JM, Campbell JD. 2025. Subsequent indications in oncology drugs: Pathways, timelines, and the Inflation Reduction Act. Ther Innov Regul Sci 59(1):102-111; doi: 10.1007/s43441-024-00706-6. PMID: 39369117.

View Abstract

Lipworth L, Panko JM, Allen BC, Mumma MT, Jiang X, Vincent MJ, Bare JL, Antonijevic T, Vivanco SN, Marano DE, Suh M, Cohen S, Mittal L, Proctor DM. 2025. Lung cancer mortality among aircraft manufacturing workers with long-term, low-level, hexavalent chromium exposure. J Occup Environ Hyg 22(3):214-227; doi: 10.1080/15459624.2024.2439817. PMID: 39773194.

View Abstract

2024

Kim A, Cong Z, Jazieh A-R, Church TR, Reichert H, Nicholson G, Fryzek J, Cohen SS. 2024. Estimating the incremental population health impact of a multi-cancer early detection (MCED) test to complement existing screening among elevated risk populations with multiple cancer risk factors: A mathematical modeling study. BMC Health Serv Res 24(1):1584; doi: 10.1186/s12913-024-12037-1. PMID: 39695574.

View Abstract